Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mind Medicine (MindMed) Inc. - Common Shares
(NQ:
MNMD
)
6.600
+0.050 (+0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine (MindMed) Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
March 07, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Mind Medicine's Earnings Outlook
February 27, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
March 01, 2024
From
MindMed
Via
Business Wire
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
February 28, 2024
Via
Benzinga
MindMed Reports 2023 Financial Results and Business Updates
February 28, 2024
From
MindMed
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
February 22, 2024
From
MindMed
Via
Business Wire
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Why Is ARB IOT (ARBB) Stock Up 230% Today?
February 13, 2024
ARB IOT stock is taking off on Tuesday after providing investors with a shareholder update and heavy trading of ARBB shares this morning.
Via
InvestorPlace
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.
Via
InvestorPlace
Exposures
Product Safety
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
February 07, 2024
From
MindMed
Via
Business Wire
Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' — This Psychedelic Bio-Tech Company Hopes To Help Build That Future
February 05, 2024
Via
Benzinga
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
January 31, 2024
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address...
Via
Benzinga
Exposures
Product Safety
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
January 11, 2024
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The...
Via
Benzinga
Why Is Clearmind (CMND) Stock Up 40% Today?
January 10, 2024
The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing.
Via
InvestorPlace
MindMed Announces Business Update and Anticipated Milestones for 2024
January 08, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
December 27, 2023
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.
Via
Talk Markets
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
Biden To Decide On Psychedelic Therapy Bill
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.